ClinicalTrials.gg
CompletedNCT03302468Updated Aug 26, 2024

Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis

An observational study in Endometriosis and Adenomyosis, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Chinese University of Hong Kong · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
448
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

Endometriosis and adenomyosis can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis.

Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has never been studied.

The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.

The hypothesis of this study is that EHP-30 (Hong Kong) traditional Chinese questionnaire has high internal consistency, construct validity, reproducibility as the original English version and can be applicable to Hong Kong Chinese women with endometriosis and adenomyosis.

Read the detailed description

Endometriosis is a chronic condition caused by the presence of ectopic endometrial tissue outside the uterus, affecting the fallopian tubes, ovaries, pelvic peritoneum or even the urinary and gastrointestinal tracts. Adenomyosis is characterized by the presence of ectopic endometrial gland and stroma in the myometrium with associated myometrial hypertrophy and hyperplasia. Adenomyosis has been reported to occur in 30-60% of the hysterectomy specimen.Endometriosis causes painful symptoms including dysmenorrhoea, pelvic pain, dyspareunia and infertility. Adenomyosis also causes clinically significant symptoms include dysmenorrhoea, pelvic pain and heavy menstrual flow.

Both conditions can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis. It also exhibits good reliability, validity and interpretability.

The EHP-30 has recently been translated into simplified Chinese version and evaluated with psychometric tests which showed the simplified Chinese version is a valid, reliable and acceptable tool for the measurement of the health-related quality of life of women with endometriosis in mainland China. Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has not been studied. The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.

EHP-30 consists of 30 items in English, grouping into five subscales measuring pain (11 items), control and powerlessness (6 items), emotions (6 items), social support (4 items) and self-image (3 items) in part one. Part two consists of 23 items, grouping into six subscales may not be applicable to all adenomyosis patients: work (5 items), relationship with children (2 items), sexual intercourse (5 items), medical profession (4 items), treatment (3 items) and infertility (4 items). Participants choose their response from a five point likert scale from 0 to 4. Items within each subscale will be added up to generate a subscale score. Then, the subscale score is divided by maximum possible score and multiply by 100 to give a health status score which 100 represent worst health and 0 represent best health status.

Firstly, approval to use EHP-30 will be obtained from the original author, Dr Georgina Jones. We will adhere to the Good Practice for the Translation and Cultural adaptation process for patient-reported outcomes measures guideline. 6 The EHP-30 will be evaluated by 2 bilingual researchers in the fields of gynaecology independently and decide if any item will be regarded as inappropriate. They will then perform the forward translation of the EHP-30 to traditional Chinese independently. After that, they will review the two versions of translation and hold a meeting for discussion on items of discrepancy, in order to produce one version. Back-translation will be performed by another 2 persons who are professional in Chinese-English translation, after the iterative evaluation of forward translation process. The original and back-translated versions will be compared for accuracy and comprehension by another two monolingual researchers. If substantial differences existed between the two original and the back-translated versions, the translation-back translation process are repeated until a questionnaire representative of the original is obtained. Finally, the back-translated version will be sent to Dr Georgina Jones and the colleagues. Comments on the back-translated version will be obtained from them.

Pilot phase of the translated questionnaire Chinese women attending the Gynaecology clinic of New Territories East Cluster with pelvic painful symptoms will be invited to join the study. Exclusion criteria include an age of less than 18 years, mental incapacity that would preclude completion of the questionnaire and those who refuse to join. Written consent will be obtained from them by a research assistant. They will be asked to complete the EHP-30 and SF-36 at the specialty clinic. After filling in the questionnaires, they will be asked to give comments on the questionnaire.

Any patient attending the gynaecology clinic who fulfills the inclusion criteria and without any exclusion criteria will be invited for participation in the study. If the patient is willing to participate, written consent will be obtained from the patient. The study investigators will record demographic features and characteristics of the disease. The patient will be asked to complete the traditional-Chinese version of EHP-30 and traditional-Chinese version of the Medical Outcomes Study Short Form 36-item health survey (SF-36). 11-13 Demographic data collected include age, height, weight, education level, marital status, monthly household income and employment status. Disease characteristics for endometriosis include intensity of painful symptoms by visual analog scale (VAS), menstrual blood loss by pictorial blood loss assessment chart (PBAC) and intraoperative scoring of the severity of endometriosis. Disease characteristics for adenomyosis include VAS scores on painful symptoms, size of uterus and size of adenomyosis and menstrual blood loss by pictorial blood loss assessment chart (PBAC).

Exploring the impact of quality of life is important to clinical practice. The Medical Outcomes Study Short Form 36-item health survey (SF-36) is a generic type of Health Related Quality of Life (HRQoL) assessment tool widely used in different disease conditions. Questionnaire which assesses eight dimensions of QoL of an individual. A higher score means a better quality of life. It has been used to study QoL in normal populations as well as patients suffering illnesses and estimating the relative burden of different diseases. 11-13

All patients are expected to spend within 30 minutes on questionnaire survey.

In order to study for test-retest reliability, patient with endometriosis and adenomyosis scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, when they attend for the pre-operative assessment clinic. The same set of EHP-30 will be completed when they are admitted for operation. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual postoperative follow up visit which is usually scheduled 3-6 months later.

In order to study for test-retest reliability, patient with endometriosis and adenomyosis not scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, at recruitment and a set of EHP-30 will be completed 2 weeks later and return by the return envelope provided. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual gynaecology follow up visit which is usually scheduled 3-6 months after treatment.

All patients will be asked to report any important health or life changes that occur between the questionnaires.

02

Conditions studied

  • Endometriosis
  • Adenomyosis
03

In context

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

This study's enrollment of 448 is above the median of 135 across 349 observational studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Eligible Chinese women attending the Gynaecology clinic of New Territories East Cluster will be invited to join the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal
  • Hong Kong Chinese women
  • diagnosed with endometriosis or adenomyosis.

Exclusion criteria

Exclusion Criteria:

  • uterine fibroid more than 5 cm
  • other premalignant or malignant conditions
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
448 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Validation of Endometriosis health profile-30 (EHP-30) traditional Chinese (Hong Kong) version

    internal consistency and construct validity

    Time frame: Baseline

07

Study locations

1 site
  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jul 2023, 95 months.

Of 155 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 95 months is above that.

Counting every sponsor, half of 182 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Oct 5, 2017
StartActual
Aug 6, 2015
Primary completionActual
Jul 31, 2023
CompletionActual
Jul 31, 2023
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03302468
Responsible party
Fung Wen Ying Linda (Associate Consultant, Chinese University of Hong Kong) — Principal investigator
First posted
Oct 5, 2017
Start date
Aug 6, 2015
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Last update
Aug 26, 2024

Study contacts

Wen Ying Fung
principal investigator · 852-35052748

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion